RP

Rapid Micro Biosystems Inc. Class A Common Stock Earnings Recaps

RPID Health Care 1 recap
Next earnings: November 6, 2026 (estimated) · full calendar
Q2 2026 Aug 9, 2026

Shares declined 16.8% following earnings as investors reacted negatively to cautious outlook signals and potential margin compression, despite solid revenue growth and record gross margins.

Key takeaways
  • Q2 revenue grew 11% year-over-year to $8.1 million, driven by 10% product revenue growth and 14% recurring revenue expansion.
  • Company placed 4 Growth Direct Systems and completed 9 system validations; validation guidance was increased to at least 27 systems for the full year.
  • Delivered a record 15% gross margin in the quarter, with confidence in reaching mid-to-high 20% margins by Q4.
  • Management emphasized ongoing customer engagement and commercial events to drive future adoption but signaled caution for the second half.
  • Despite operational progress, investor concerns likely stem from cautious outlook elements and possible deceleration or margin risks implicit in commentary.
Full recap

Go deeper on RPID and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.